PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Cash & equivalents declining -3.88% while Biotechnology shows -9.56% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Below half the Biotechnology median of -8.51% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-4.12%
0.5-0.75x the Biotechnology median of -7.89%. Guy Spier might worry about liquidity trailing peers.
-3.46%
PP&E growth ≥ 1.5x the Biotechnology median of -1.78%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-3.14%
≥ 1.5x the Biotechnology median of -0.92%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
0.5-0.75x Biotechnology median of -5.75%. Guy Spier is cautious about potential underinvestment relative to sector.
36.45%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
25.40%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-25.40%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
32.92%
Above 1.5x Biotechnology median of 4.78%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Below half Biotechnology median of -2.00%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
4.45%
Above 1.5x Biotechnology median of 0.83%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
0.5-0.75x Biotechnology median of -5.56%. Guy Spier is cautious about weaker retention vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
Near Biotechnology median of -8.27%. Charlie Munger sees typical yoy changes in shareholders' equity.
-4.09%
0.5-0.75x Biotechnology median of -5.81%. Guy Spier is cautious about underexpansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
Above 1.5x Biotechnology median of -0.36%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
3.93%
Below half of Biotechnology median 12.57%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.